Previous studies indicate that patients with asthma commonly have comorbidities, which may complicate their response to treatment. To examine the response omalizumab in patients with moderate-to-severe allergic asthma by both asthma-related and allergic comorbidities, investigators estimated adjusted exacerbation rates and FEV1 change from baseline following omalizumab initiation by number of comorbidities—allergic rhinoconjunctivitis, chronic rhinosinusitis, recurrent acute sinusitis, nasal polyps, atopic and contact dermatitis, urticaria, food allergy, anaphylaxis, other allergies, gastroesophageal reflux disease, eosinophilic esophagitis, and eosinophilic granulomatosis with polyangiitis—among participants of four omalizumab studies: 008/009, EXTRA, INNOVATE, and PROSPERO. “In these analyses of placebo-controlled/single-armed studies, on-study exacerbation rates and FEV1 improvements with omalizumab treatment were similar irrespective of comorbidity burden,” concluded the study authors.